Principal Investigator
Jaime Merchan
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20230681
Clinical Trial Summary
A Phase 1, open-label, dose escalation and dose expansion study, to investigate the safety, tolerability, and pharmacokinetic profile of AB521 monotherapy and in combination therapies in participants with clear cell renal cell carcinoma and other solid tumors
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647